Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rosiglitazone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2011
Lead Product(s) : Rosiglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosiglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2011
Lead Product(s) : Rosiglitazone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosiglitazone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2010
Lead Product(s) : Rosiglitazone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosiglitazone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2010
Lead Product(s) : Rosiglitazone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable